The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee Company Update: Nuuvera

21 Mar 2018 13:28

RNS Number : 4747I
FastForward Innovations Limited
21 March 2018
 

 

21 March 2018

 

FastForward Innovations Limited

("FastForward"")

Investee Company Update:

UPDATE ON PLAN OF ARRANGEMENT WITH APHIRA INC.

FastForward notes the announcement today by investee company Nuuvera Inc. ("Nuuvera" (TSXV: NUU)), a public company formed to capitalize on the global trend towards the legalisation of medical cannabis, in which FastForward currently has a holding of 3.4%. The announcement is set out below without material changes or adjustments:

LEAMINGTON, ON and TORONTOMarch 20, 2018 /CNW/ - Nuuvera Inc. (the "Company" or "Nuuvera") (TSXV:NUU) and Aphria Inc. ("Aphria") (TSX: APH and US OTC: APHQF) are pleased to announce that, at the special meeting of shareholders of Nuuvera held today (the "Meeting"), the shareholders of Nuuvera overwhelmingly voted in favour of a special resolution to approve the proposed plan of arrangement with Aphria previously announced on January 29, 2018(the "Arrangement") pursuant to which, among other things, Aphria will acquire all of the issued and outstanding shares of Nuuvera not already owned by it.

 

The Arrangement required approval by: (i) 66⅔% of the votes cast by shareholders present in person or represented by proxy at the Meeting; and (ii) a simple majority of the votes cast by shareholders present in person or represented by proxy at the Meeting, excluding the votes cast by such shareholders as are required to be excluded pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101").

 

A total of 60,129,430 Nuuvera shares, representing approximately 67.15% of the outstanding Nuuvera shares, were represented in person or by proxy at the Meeting. Of the votes cast with respect to the Arrangement, an aggregate of 60,073,288 Nuuvera shares were voted in favour of the Arrangement, representing approximately 99.90% of the votes cast on the resolution. In addition, an aggregate of 47,193,288 Nuuvera shares, representing approximately 99.88% of the votes cast on the resolution excluding such shareholders as are required to be excluded pursuant to MI 61-101, were voted in favour of the Arrangement.

 

It is expected that Nuuvera will apply for a final order of the Ontario Superior Court of Justice (Commercial List) on March 22, 2018. Completion of the Arrangement remains subject to other customary closing conditions, including the aforementioned court order. Assuming that the conditions to closing are satisfied or waived, it is expected that the Arrangement will be completed on or around March 23, 2018. Following completion of the Arrangement, Nuuvera will be de-listed from the TSX Venture Exchange and applications will be made for Nuuvera to cease to be a reporting issuer.

 

Further information about the Arrangement is set forth in the materials prepared by the Company in respect of the Meeting which were mailed to Nuuvera shareholders and filed under Nuuvera's profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

 

About Nuuvera

 

Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in GermanyIsrael and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA - Avanti and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its "letter to build" approval.

 

For more information about Nuuvera, please visit: www.nuuvera.com

 

CONTACTS:

 

FastForward Innovations Limited info@fstfwd.co

Sue Saunders/ Ian Burns

Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396

James Biddle / Roland Cornish

Optiva Securities Limited (Broker) Tel: +44 (0) 203 411 1881

Ed McDermott

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUAUORWBAOUAR
Date   Source Headline
25th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
18th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
11th Feb 20207:00 amRNSUpdated Key Information Document
31st Jan 20201:30 pmRNSInvestee Company Update: Portage Biotech Inc.
8th Jan 20207:00 amRNSDisposal of Interest in Cryptologic Corp
7th Jan 20207:00 amRNSBoard Appointment
3rd Jan 20201:15 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Dec 20197:00 amRNSHalf-year Report
5th Dec 20192:45 pmRNSTR-1 Notification
19th Nov 20197:00 amRNSLorne Abony appointed as Chairman of EMMAC
16th Oct 20197:00 amRNSInvestee Company Update: EMMAC Life Sciences
15th Oct 20197:00 amRNSInvestee Company Update: Factom inc.
10th Oct 20199:25 amRNSResult of 2019 AGM
27th Sep 20194:31 pmRNSDirector Dealing in the Company
27th Sep 20197:00 amRNSInvestee Company Update : Fralis LLC (Leap Gaming)
26th Sep 201911:21 amRNSInvestee Company Update : Cryptologic Corp
16th Sep 201911:52 amRNSTR-1 Notification of major holdings
11th Sep 20198:00 amRNSResults for the year ended 31st March 2019
11th Sep 20198:00 amRNSNotice of 2019 Annual General Meeting
22nd Aug 201912:01 pmRNSDirectorate Change
19th Aug 20199:23 amRNSJuvenescence closes Series B funding
12th Aug 20193:02 pmRNSInvestee Company Update-Cryptologic issues loan
12th Aug 201910:11 amRNSPortage Trading Suspended
6th Aug 20194:42 pmRNSInvestee Company Update: Cryptologic Corp
30th Jul 201911:07 amRNSSAFE Agreement with Factom, Inc. Extended
25th Jul 20198:17 amRNSFactom Inc SAFE Agreement temporary extension
18th Jul 201911:20 amRNSInvestee Company Update: Regent Pacific on Yooya
16th Jul 20199:13 amRNSInvestee Company Update:EMMAC acquires Terre Verde
11th Jul 20193:00 pmRNSDisposal of interest in Intensity Therapeutics Inc
9th Jul 201910:51 amRNSInvestee Company Update: EMMAC enters new Market
26th Jun 20198:56 amRNSInvestee Company Update: Intensity Therapeutics
29th May 20193:43 pmRNSInvestee Company Update: Offer for Yooya
13th May 201910:21 amRNSDisposal of interest in Vemo Education Inc.
18th Apr 20197:00 amRNSInvestee Company Update: Intensity Therapeutics
4th Apr 20199:51 amRNSTR1 - Correction
3rd Apr 20194:00 pmRNSTR:1 Regent Mercantile Holdings Limited
20th Mar 201911:00 amRNSCompletion of £2 million investment in EMMAC
7th Mar 20194:03 pmRNS£2 million investment in EMMAC Life Sciences
15th Jan 20193:45 pmRNSJuvenescence Series B Funding
3rd Jan 201911:47 amRNSBoard Appointment
12th Dec 201812:52 pmRNSHalf-year Report
3rd Dec 20187:00 amRNSInvestee Company Update: Factom and Yooya
14th Nov 20181:31 pmRNSInvestee Company Update: Factom Inc
22nd Oct 201812:24 pmRNSIntensity Therapeutics Inc Update
12th Sep 20186:12 pmRNSResult of AGM
10th Sep 20189:16 amRNSHolding(s) in Company
22nd Aug 20188:08 amRNSDirector Dealing
3rd Aug 201812:48 pmRNSShareholder update
3rd Aug 20188:00 amRNSPlacing
1st Aug 201812:05 pmRNSResponse to Media Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.